Scholarlink

Background <p>Lung adenocarcinoma (LUAD), the most prevalent type of lung cancer, displays marked molecular and cellular heterogeneity driven by diverse oncogenic alterations. Many of these changes are thought to occur during the transformation of alveolar type 2 (AT2) cells, which function as stem-like progenitors and likely cells of origin for LUAD. To investigate the regulatory mechanisms underlying AT2 cell transformation and intratumoral heterogeneity, we performed single-nucleus RNA sequencing (snRNA-seq) and single-nucleus Assay for Transposase-Accessible Chromatin sequencing (snATAC-seq) as a multiome assay.</p> Results <p>Tumor specimens from two LUAD patients with TP53 mutations, one harboring a ROS1 fusion, were analyzed. snRNA-seq defined major cell populations and distinguished tumor cells from AT2 cells based on inferred copy number alterations. Integration with snATAC-seq data identified differentially accessible chromatin regions and their linked target genes through peak-to-gene associations. Trajectory inference indicated a gradual transition from AT2 to tumor cell states in one case, accompanied by transcription factor-driven epigenomic remodeling. In contrast, the <i>ROS1</i> fusion case exhibited a breakpoint between <i>SLC34A2</i> (exon 13) and <i>ROS1</i> (exons 31–32), associated with PI3K/AKT/mTOR pathway activation and distinct gene activity profiles.</p> Conclusions <p>These findings indicate patient-specific patterns of tumor evolution in LUAD, with one case showing a progressive AT2-to-tumor transition and another driven by <i>ROS1</i> fusion-mediated oncogenic signaling. Together, they highlight how transcriptional and epigenetic programs diverge across tumor contexts, contributing to inter-patient heterogeneity in LUAD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Single-nucleus multi-omics delineates distinct epigenetic programs associated with tumor progression in lung adenocarcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月11日

查看全文
  • Yeji Kim,
  • Huiram Kang,
  • Yongki Hwang,
  • Kyung Soo Kim,
  • Seok Whan Moon,
  • Jeonghan Kim,
  • Seung Joon Kim,
  • Hae-Ock Lee

摘要

Background

Lung adenocarcinoma (LUAD), the most prevalent type of lung cancer, displays marked molecular and cellular heterogeneity driven by diverse oncogenic alterations. Many of these changes are thought to occur during the transformation of alveolar type 2 (AT2) cells, which function as stem-like progenitors and likely cells of origin for LUAD. To investigate the regulatory mechanisms underlying AT2 cell transformation and intratumoral heterogeneity, we performed single-nucleus RNA sequencing (snRNA-seq) and single-nucleus Assay for Transposase-Accessible Chromatin sequencing (snATAC-seq) as a multiome assay.

Results

Tumor specimens from two LUAD patients with TP53 mutations, one harboring a ROS1 fusion, were analyzed. snRNA-seq defined major cell populations and distinguished tumor cells from AT2 cells based on inferred copy number alterations. Integration with snATAC-seq data identified differentially accessible chromatin regions and their linked target genes through peak-to-gene associations. Trajectory inference indicated a gradual transition from AT2 to tumor cell states in one case, accompanied by transcription factor-driven epigenomic remodeling. In contrast, the ROS1 fusion case exhibited a breakpoint between SLC34A2 (exon 13) and ROS1 (exons 31–32), associated with PI3K/AKT/mTOR pathway activation and distinct gene activity profiles.

Conclusions

These findings indicate patient-specific patterns of tumor evolution in LUAD, with one case showing a progressive AT2-to-tumor transition and another driven by ROS1 fusion-mediated oncogenic signaling. Together, they highlight how transcriptional and epigenetic programs diverge across tumor contexts, contributing to inter-patient heterogeneity in LUAD.